BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2025-10

211 industry Phase 2/3 trial readout(s) and 61 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2025-09 | 2025-11 →

FDA decision events

DateEventStatusCompanyDrugSource
2025-10-02FDA approvalapprovedNOVARTIS NVSSCEMBLIXApproved 2025-10-02: SCEMBLIX (NDA215358 SUPPL10)
2025-10-02FDA approvalapprovedJAZZ JAZZZEPZELCAApproved 2025-10-02: ZEPZELCA (NDA213702 SUPPL11)
2025-10-02FDA approvalapprovedGENENTECH INCTECENTRIQ HYBREZAApproved 2025-10-02: TECENTRIQ HYBREZA (BLA761347 SUPPL3)
2025-10-02FDA approvalapprovedCELLTRION INCEYDENZELTApproved 2025-10-02: EYDENZELT (BLA761377 ORIG1)
2025-10-02FDA approvalapprovedGENENTECH INCTECENTRIQApproved 2025-10-02: TECENTRIQ (BLA761034 SUPPL58)
2025-10-03FDA approvalapprovedAVYXA HOLDINGSAXTLEApproved 2025-10-03: AXTLE (NDA210661 SUPPL4)
2025-10-04FDA approvalapprovedARCUTIS ARQTZORYVEApproved 2025-10-04: ZORYVE (NDA215985 SUPPL12)
2025-10-07Complete response lettercomplete responseXspray Pharma AB©® ‘(dasatinib) tabletsCRL 2025-10-07: Xspray Pharma AB NDA 216195 (©® ‘(dasatinib) tablets)
2025-10-07FDA approvalapprovedBOEHRINGER INGELHEIMJASCAYDApproved 2025-10-07: JASCAYD (NDA218764 ORIG1)
2025-10-07FDA approvalapprovedCENTOCOR ORTHO BIOTECH INCSIMPONIApproved 2025-10-07: SIMPONI (BLA125289 SUPPL157)
2025-10-07FDA approvalapprovedSQ INNOVATIONLASIX ONYUApproved 2025-10-07: LASIX ONYU (NDA217294 ORIG1)
2025-10-08FDA AdComheldAdCom 2025-10-08: General Hospital and Personal Use Devices Panel of the Medical Devices Advisory Committee
2025-10-08FDA AdComheldAdCom 2025-10-08: General Hospital and Personal Use Devices Panel of the Medical Devices Advisory Committee
2025-10-08FDA approvalapprovedREGENERON PHARMACEUTICALS REGNLIBTAYOApproved 2025-10-08: LIBTAYO (BLA761097 SUPPL30)
2025-10-09FDA AdComheldAdCom 2025-10-09: Vaccines and Related Biological Products Advisory Committee
2025-10-09FDA approvalapprovedREGENERON PHARMACEUTICALS REGNPRALUENTApproved 2025-10-09: PRALUENT (BLA125559 SUPPL47)
2025-10-10Complete response lettercomplete responseAstraZeneca Pharmaceuticals LP AZNanifrolumabCRL 2025-10-10: AstraZeneca Pharmaceuticals LP BLA 761451 (anifrolumab)
2025-10-10FDA approvalapprovedTAKEDA PHARMS USA TAKICLUSIGApproved 2025-10-10: ICLUSIG (NDA203469 SUPPL38)
2025-10-10FDA approvalapprovedABBVIE ABBVRINVOQApproved 2025-10-10: RINVOQ (NDA211675 SUPPL28)
2025-10-10FDA approvalapprovedTEVA TEVAUZEDYApproved 2025-10-10: UZEDY (NDA213586 SUPPL8)
2025-10-10FDA approvalapprovedBRACCOISOVUE-128; ISOVUE-200; ISOVUE-250; ISOVUE-300; ISOVUE-370; ISOVUE-M 200; ISOVUE-M 300Approved 2025-10-10: ISOVUE-128; ISOVUE-200; ISOVUE-250; ISOVUE-300; ISOVUE-370; ISOVUE-M 200; ISOVUE-M 300 (NDA018735 SUPPL75)
2025-10-10FDA approvalapprovedACEROLPRUVAApproved 2025-10-10: OLPRUVA (NDA214860 SUPPL7)
2025-10-15FDA approvalapprovedMERCK SHARP AND DOHME LLC MRKApproved 2025-10-15: (BLA761495 ORIG1)
2025-10-16Complete response lettercomplete responseDr. Reddy’s Laboratories SADRL_RICRL 2025-10-16: Dr. Reddy’s Laboratories SA BLA 761376 (DRL_RI)
2025-10-16FDA approvalapprovedAZURITYFERABRIGHTApproved 2025-10-16: FERABRIGHT (NDA219868 ORIG1)
2025-10-16FDA approvalapprovedIMMEDICA PHARMAZTALMYApproved 2025-10-16: ZTALMY (NDA215904 SUPPL11)
2025-10-16FDA approvalapprovedPFIZER PFEXELJANZApproved 2025-10-16: XELJANZ (NDA213082 SUPPL11)
2025-10-16FDA approvalapprovedPF PRISM CVXELJANZApproved 2025-10-16: XELJANZ (NDA203214 SUPPL39)
2025-10-17FDA approvalapprovedARGENX BVVYVGARTApproved 2025-10-17: VYVGART (BLA761195 SUPPL12)
2025-10-17FDA approvalapprovedASTRAZENECA AB AZNTEZSPIREApproved 2025-10-17: TEZSPIRE (BLA761224 SUPPL6)
2025-10-17FDA approvalapprovedGLAUKOS GKOSEPIOXA HD/EPIOXA KITApproved 2025-10-17: EPIOXA HD/EPIOXA KIT (NDA219910 ORIG1)
2025-10-17FDA approvalapprovedARGENX BVVYVGART HYTRULOApproved 2025-10-17: VYVGART HYTRULO (BLA761304 SUPPL10)
2025-10-17FDA approvalapprovedNOVO NVORYBELSUSApproved 2025-10-17: OZEMPIC; RYBELSUS (NDA213051 SUPPL24)
2025-10-17FDA approvalapprovedGENENTECHGAZYVAApproved 2025-10-17: GAZYVA (BLA125486 SUPPL38)
2025-10-17FDA approvalapprovedGENENTECHGAZYVAApproved 2025-10-17: GAZYVA (BLA125486 SUPPL37)
2025-10-20FDA approvalapprovedASTRAZENECA AB AZNBEYFORTUSApproved 2025-10-20: BEYFORTUS (BLA761328 SUPPL12)
2025-10-21Complete response lettercomplete responseNeuroDerm, Ltd.CRL 2025-10-21: NeuroDerm, Ltd. NDA 218317
2025-10-22Complete response lettercomplete responseSYDNEXIS Inc.atropine sulfate ophthalmic solution, 0CRL 2025-10-22: SYDNEXIS Inc. NDA 219694 (atropine sulfate ophthalmic solution, 0)
2025-10-22FDA approvalapprovedMEITHEALCONTEPOApproved 2025-10-22: CONTEPO (NDA212271 ORIG1)
2025-10-22FDA approvalapprovedLundbeck Seattle BioPharmaceuticals, Inc.VYEPTIApproved 2025-10-22: VYEPTI (BLA761119 SUPPL11)
2025-10-23Complete response lettercomplete responseShanghai Auzone Biological Technology Co., Ltd.CRL 2025-10-23: Shanghai Auzone Biological Technology Co., Ltd. NDA 219846
2025-10-23Complete response lettercomplete responseGlaxoSmithKline LLCBlenrep (belantamab mafodotin-blmf) injectionCRL 2025-10-23: GlaxoSmithKline LLC BLA 761440/Original 2, BLA 761440 (Blenrep (belantamab mafodotin-blmf) injection)
2025-10-23FDA approvalapprovedBE PHARMSDEHYDRATED ALCOHOLApproved 2025-10-23: DEHYDRATED ALCOHOL (NDA214988 ORIG1)
2025-10-23FDA approvalapprovedGLAXOSMITHKLINE LLCBLENREPApproved 2025-10-23: BLENREP (BLA761440 ORIG1)
2025-10-23FDA approvalapprovedAZURITYJAVADINApproved 2025-10-23: JAVADIN (NDA220256 ORIG1)
2025-10-24FDA approvalapprovedMERCK SHARP DOHME MRKWINREVAIRApproved 2025-10-24: WINREVAIR (BLA761363 SUPPL7)
2025-10-24FDA approvalapprovedSYNDAX SNDXREVUFORJApproved 2025-10-24: REVUFORJ (NDA218944 SUPPL3)
2025-10-24FDA approvalapprovedBAYER HLTHCARELYNKUETApproved 2025-10-24: LYNKUET (NDA219469 ORIG1)
2025-10-24FDA approvalapprovedB BRAUN MEDICALROCURONIUM BROMIDEApproved 2025-10-24: ROCURONIUM BROMIDE (NDA219108 ORIG1)
2025-10-25FDA approvalapprovedROBERTS OXYGEN CO INCCARBON DIOXIDE USPApproved 2025-10-25: CARBON DIOXIDE, USP (NDA221021 ORIG1)
2025-10-27FDA approvalapprovedBRISTOL-MYERS SQUIBB BMYOPDIVO QVANTIGApproved 2025-10-27: OPDIVO QVANTIG (BLA761381 SUPPL2)
2025-10-27FDA approvalapprovedBRISTOL-MYERS SQUIBB BMYOPDIVO QVANTIGApproved 2025-10-27: OPDIVO QVANTIG (BLA761381 SUPPL1)
2025-10-29FDA approvalapprovedSAMSUNG BIOEPIS CO LTDDENOSUMAB-DSSB; OSPOMYV; XBRYKApproved 2025-10-29: DENOSUMAB-DSSB; OSPOMYV; XBRYK (BLA761392 ORIG2)
2025-10-29FDA approvalapprovedFRESENIUS KABI USA LLCBOMYNTRA; CONEXXENCEApproved 2025-10-29: BOMYNTRA; CONEXXENCE (BLA761398 ORIG2)
2025-10-29FDA approvalapprovedCELLTRION INCOSENVELT; STOBOCLOApproved 2025-10-29: OSENVELT; STOBOCLO (BLA761404 ORIG2)
2025-10-29FDA approvalapprovedACCORD BIOPHARMA INC.JUBEREQ; OSVYRTIApproved 2025-10-29: JUBEREQ; OSVYRTI (BLA761424 ORIG1)
2025-10-29FDA approvalapprovedBIOCON BIOLOGICS INCAUKELSO; BOSAYAApproved 2025-10-29: AUKELSO; BOSAYA (BLA761436 ORIG2)
2025-10-29FDA approvalapprovedHIKMA PHARMACEUTICALS USA INCENOBY; XTRENBOApproved 2025-10-29: ENOBY; XTRENBO (BLA761439 ORIG2)
2025-10-29FDA approvalapprovedSHANGHAI HENLIUS BIOTECHBILDYOS; BILPREVDAApproved 2025-10-29: BILDYOS; BILPREVDA (BLA761444 ORIG2)
2025-10-29FDA approvalapprovedREGENERON PHARMACEUTICALS REGNLIBTAYOApproved 2025-10-29: LIBTAYO (BLA761097 SUPPL32)
2025-10-31Complete response lettercomplete responseAlvotech USA Inc. ALVOAVTO5CRL 2025-10-31: Alvotech USA Inc. BLA 761462 (AVTO5)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2025-10 est.P3NS Pharma, Inc.NCT04768062 Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)Duchenne Muscular Dystrophyactive not recruiting74
2025-10 est.P1/P2Telios Pharma, Inc.NCT05280509 Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to RuxolitinibMyelofibrosis; Primary Myelofibrosis; Post-PV MF; Post-ET Myelofibrosisrecruiting70
2025-10 est.P3Shanghai Miracogen Inc.NCT05754853 A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial CaAdvanced or Metastatic Urothelium Cancerrecruiting290
2025-10 est.P1/P2Guangzhou Excelmab Inc.NCT06021678 Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin LymphomaCD20-positive Non-Hodgkin Lymphomarecruiting415
2025-10 est.P2Tasly Pharmaceutical Group Co., LtdNCT06058546 Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque PsoriasisPlaque Psoriasisunknown180
2025-10 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT06308406 A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian CancerRecurrent Ovarian Cancerunknown54
2025-10 est.P2Areteia TherapeuticsNCT06533553 A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPDChronic Obstructive Pulmonary Diseaseactive not recruiting30
2025-10 est.P3Tonghua Dongbao Pharmaceutical Co.,LtdNCT06559722 A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 DiabetesType 2 Diabetesunknown510
2025-10 est.P2Aurion BiotechNCT06630169 Study of Cryopreserved AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial DysfunctionCorneal Edemaactive not recruiting25
2025-10 est.P2Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT06854445 Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell LymphomaDiffuse Large Cell B-lymphomarecruiting55
2025-10 est.P2Guangdong Hengrui Pharmaceutical Co., LtdNCT06940700 Clinical Study on the Efficacy and Safety of SHR-4597 Inhalant in Adult Patients With AsthmaAsthmanot yet recruiting60
2025-10 est.P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07011186 A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid MalignanciesMyeloid Malignancyrecruiting138
2025-10-01P3Hoffmann-La RocheNCT03456063 A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small CellNon-Small-Cell Lungcompleted453
2025-10-01 est.P2CellSight Technologies, Inc.NCT03684655 Imaging Immune Activation in HIV by PET-MRHIV Infectionsunknown30
2025-10-01P2Hi-Q Marine Biotech International, Ltd.NCT04597476 A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and NeckSquamous Cell Carcinomas of the Head and Neckcompleted69
2025-10-01P2Bioverativ, a Sanofi companyNCT04658472 Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Chronic Inflammatory Demyelinating Polyradiculoneuropathycompleted98
2025-10-01 est.P2Anterogen Co., Ltd.NCT05157958 Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis BullosaDystrophic Epidermolysis Bullosaunknown6
2025-10-01 est.P2Virogin Biotech Canada LtdNCT05223816 An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With NHepatocellular Carcinoma; Intrahepatic Cholangiocarcinomaunknown97
2025-10-01P3Dexa Medica GroupNCT05248802 DLBS2411 Treatment For Functional DyspepsiaFunctional Dyspepsiacompleted106
2025-10-01P3Harmony Biosciences Management, Inc. HRMYNCT05458128 A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic HypersomniaIdiopathic Hypersomnia; Excessive Daytime Sleepinesscompleted119
2025-10-01P2Eli Lilly and Company LLYNCT05936151 A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesOverweight or Obesity; CKD; Type 2 Diabetescompleted146
2025-10-01P2Sanofi SNYNCT06015308 A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With PlaceboDermatitis Atopiccompleted224
2025-10-01P3Bristol-Myers Squibb BMYNCT06045689 A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome ParticipantsMyelodysplastic Syndromesactive not recruiting106
2025-10-01P2GlaxoSmithKlineNCT06317285 A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosisterminated158
2025-10-01P3Novo Nordisk A/S NVONCT06323174 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseType 2 Diabetescompleted189
2025-10-01P2Rallybio RLYBNCT06435845 Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a AlloimmunizationFetal and Neonatal Alloimmune Thrombocytopeniaterminated1
2025-10-01P2Novo Nordisk A/S NVONCT06542874 A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesType 2 Diabetes (T2D)completed448
2025-10-01 est.P2Zhejiang Kanova Biopharmaceutical Co., LTDNCT07054736 Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic DermatitisAtopic Dermatitisnot yet recruiting120
2025-10-02P1/P2Ryvu Therapeutics SANCT05052255 RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid TumorsAdvanced Solid Tumorterminated66
2025-10-02 est.P2Merck Sharp & Dohme LLC MRKNCT05115838 Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)Human Immunodeficiency Virus; HIVwithdrawn
2025-10-02P3Sanofi SNYNCT05222906 Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3Gaucher's Disease Type IIIactive not recruiting43
2025-10-02P3AstraZeneca AZNNCT05771480 Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)Biliary Tract Canceractive not recruiting142
2025-10-02P3Daewoong Pharmaceutical Co. LTD.NCT06682000 Efficacy and Safety of DWC202404 and DWC202314 in Patients With HypertensionHypertension; Essential Hypertensioncompleted192
2025-10-03P2Hope Biosciences Research FoundationNCT04995081 Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)Parkinson Diseasecompleted60
2025-10-03P2Pfizer PFENCT05429372 Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular DystrophyMuscular Dystrophy, Duchenneterminated10
2025-10-03P2Aadi Bioscience, Inc.NCT05997056 Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Neuroendocrine Tumors; NET; Pancreatic Neuroendocrine Tumor; Gastrointestinal Neuroendocrine Tumor; completed12
2025-10-03P1/P2Entos Pharmaceuticals Inc.NCT06436911 To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNACOVID-19completed46
2025-10-03P2Allay Therapeutics, Inc.NCT06799845 Phase 2B Study Assessing Pain Relief After Replacement of the KneeTotal Knee Arthroplasty (Postoperative Pain)completed226
2025-10-03P3Dexa Medica GroupNCT07420491 The Efficacy and Safety of Reconyl in Acute Cough TreatmentCoughcompleted144
2025-10-05P2AM-PharmaNCT06168799 Ilofotase Alfa for Prevention of Renal Damage After Cardiac SurgeryOpen Heart Surgerycompleted271
2025-10-06P3AbbVie ABBVNCT04578756 Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Schizophrenia; Bipolar I Disorder; Autism Spectrum Disorder (ASD)completed310
2025-10-06P1/P2Artiva Biotherapeutics, Inc. ARTVNCT04673617 AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin LymphomaNon Hodgkin Lymphomacompleted45
2025-10-06P3AstraZeneca AZNNCT05450692 A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After PrioAdvanced or Metastatic Non-Small Cell Lung Canceractive not recruiting594
2025-10-06P1/P2Integro TheranosticsNCT05900986 LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast CancerBreast Cancer; DCIS; Invasive Duct Carcinoma of Breastcompleted22
2025-10-06P2Transcend TherapeuticsNCT06237426 An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSDPost Traumatic Stress Disordercompleted44
2025-10-06P2Amgen AMGNNCT06660173 A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)Type 2 Diabetes Mellitus (T2DM)active not recruiting409
2025-10-06P2Vanda Pharmaceuticals VNDANCT06804603 A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist UseObesitycompleted124
2025-10-07P3ActelionNCT04273945 Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial HypertensionPulmonary Arterial Hypertensionactive not recruiting935
2025-10-07P3Alexion Pharmaceuticals, Inc.NCT05746559 ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKEChronic Kidney Disease; CKD; Cardiac Disease; Cardiopulmonary Bypassterminated555
2025-10-07P2BayerNCT06149520 A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein ThrombosisThrombolysis; Symptomatic Proximal Deep Vein Thrombosiscompleted283
2025-10-07P3Teva Pharmaceuticals USANCT06742957 Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque PsoriasisPlaque Type Psorisiscompleted560
2025-10-07P2BioXcel Therapeutics Inc BTAIQNCT07116694 Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar DisorderBipolar I Disorder; Bipolar II Disorder; Schizophrenia; Schizoaffective Disorder; Schizophreniform Dcompleted33
2025-10-08 est.P3Novartis Pharmaceuticals NVSNCT03628053 Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemiawithdrawn
2025-10-08P1/P2Hoffmann-La RocheNCT03869190 Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)Urothelial Carcinoma; Bladder Cancerterminated272
2025-10-08P1/P2Beijing Biostar Pharmaceuticals Co., Ltd.NCT05700084 Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid TumorsAdvanced Solid Tumoractive not recruiting84
2025-10-08P2Lakefront Biotherapeutics NV LKFTNCT05856448 A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus ErythematosusSystemic Lupus Erythematosuscompleted186
2025-10-08P3Hangzhou Gensciences Biopharmaceutical Co., Ltd.NCT06142552 Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinSevere Hemophilia Acompleted124
2025-10-08 est.P2Shin Poong Pharmaceutical Co. Ltd.NCT06826872 Efficacy and Safety of SPC1001 in Patients With Essential HypertensionHypertension, Essential; Cardiovascular Diseases; Cardiologyrecruiting252
2025-10-08P2IVIEW Therapeutics Inc.NCT07140380 Phase 2b Controlled StudyDry Eye Diseasecompleted30
2025-10-09P1/P2Hoffmann-La RocheNCT03281369 A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal JunctionGastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinomaterminated219
2025-10-09P1/P2Pharmacyclics LLC.NCT03790332 Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)Chronic Graft Versus Host Diseasecompleted59
2025-10-09P3Hoffmann-La RocheNCT04861259 A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic UremicAtypical Hemolytic Uremic Syndromeactive not recruiting83
2025-10-09P2AbbVie ABBVNCT05105841 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult PaChronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)completed20
2025-10-09P1/P2ImCheck Therapeutics, an Ipsen companyNCT05307874 Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid TumorsSolid Tumor, Adultterminated56
2025-10-09P2Sanofi SNYNCT06028230 A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaHidradenitis Suppurativaterminated70
2025-10-09P2Ono Pharmaceutical Co., Ltd.NCT06256328 A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Gastric Canceractive not recruiting226
2025-10-09P3Boehringer IngelheimNCT06309992 A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic SteatohepObesity; Non-Alcoholic SteatoHepatitis (NASH)completed218
2025-10-09P1/P2Servier Bio-Innovation LLCNCT06563804 A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMMLRelapsed/Refractory (R/R) Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)/AML; Chronic terminated13
2025-10-09P2Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT06609460 Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza ComplicationsInfluenzacompleted5071
2025-10-09P1/P2Ventus Therapeutics U.S., Inc.NCT06822517 A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's DiseaseParkinson Diseaseterminated29
2025-10-10P2Zetagen Therapeutics, IncNCT05280067 ZETAMET™ BONE GRAFT IN THE REPAIR OF BONE DEFECTS FROM METASTATIC BREAST CANCER IN VERTEBRAL BONESMetastatic Breast Cancer in the Spinecompleted10
2025-10-10P3Praxis Precision Medicines PRAXNCT06087276 Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)Essential Tremorrecruiting1000
2025-10-10P2/P3Neurocentria, Inc.NCT06215144 Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHDAttention-Deficit/Hyperactivity Disorder (ADHD)terminated95
2025-10-10P2Cardurion Pharmaceuticals, Inc.NCT06215911 A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)Heart Failure; Heart Failure With Reduced Ejection Fraction; Cardiovascular Diseases; Heart Diseasescompleted557
2025-10-11P1/P2InxMed (Shanghai) Co., Ltd.NCT05827796 IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic CancerPancreatic Canceractive not recruiting70
2025-10-13P3ImmunityBio, Inc. IBRXNCT03520686 Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerNon Small Cell Lung Cancerterminated102
2025-10-13P1/P2Cullinan Therapeutics Inc. CGEMNCT04036682 A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung CancerNon Small Cell Lung Cancer; EGFR Exon 20 Mutationactive not recruiting284
2025-10-13P2ImmunityBio, Inc. IBRXNCT04390399 Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic PancreaticPancreatic Canceractive not recruiting328
2025-10-13P3BeiGeneNCT04486391 Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin LymphomaClassical Hodgkin Lymphomaterminated3
2025-10-13P3Genmab GMABNCT04628494 A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)Diffuse Large B-cell Lymphomaactive not recruiting483
2025-10-13P3Janssen Research & Development, LLCNCT05572515 A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed Multiple Myelomaactive not recruiting614
2025-10-13P2Lakefront Biotherapeutics NV LKFTNCT05695950 A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With DermatomyositisDermatomyositiscompleted40
2025-10-13P3Merck Sharp & Dohme LLC MRKNCT05705349 DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)HIV-1 Infectionactive not recruiting537
2025-10-13P2Rose Research Center, LLCNCT05994703 Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserineSmoking Cessation; Harm Reductioncompleted25
2025-10-13P3Astellas Pharma Global Development, Inc.NCT05999747 A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney DiseaseIntraoperative Ureter Visualization; Abdominolpelvic Surgerycompleted95
2025-10-13P2Tempero Bio, Inc.NCT06648655 A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use DisorderAlcohol Use Disorder (AUD)terminated110
2025-10-13P3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT06648772 Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 StudyPlaque Psoriasiscompleted190
2025-10-13P3Taisho Pharmaceutical Co., Ltd.NCT06745531 A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on HemodialysisHyperphosphatemia Patients on Hemodialysiscompleted101
2025-10-13P2ModernaTX, Inc.NCT06864143 A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of AgeInfluenza; SARS-CoV-2completed1320
2025-10-13P3Genmab GMABNCT07226752 A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in ChinaDiffuse Large B-Cell Lymphomaactive not recruiting72
2025-10-14P3Merck Sharp & Dohme LLC MRKNCT03036488 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in PartiTriple Negative Breast Neoplasmscompleted1174
2025-10-14 est.P3Biogen BIIBNCT03070132 802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal NeuralgiaTrigeminal Neuralgiawithdrawn
2025-10-14P1/P2Hoffmann-La RocheNCT03337698 A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)Carcinoma, Non-Small-Cell Lungterminated314
2025-10-14P2Intercept PharmaceuticalsNCT04594694 Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBCPrimary Biliary Cholangitisterminated75
2025-10-14P2Novartis Pharmaceuticals NVSNCT04641442 Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP DNLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutationsactive not recruiting17
2025-10-14P3Amgen AMGNNCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal JunctioGastric Cancer; Gastroesophageal Junction Adenocarcinomaterminated515
2025-10-14P2Cybin IRL LimitedNCT06051721 A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)Generalized Anxiety Disordercompleted36
2025-10-14P3Colgate Palmolive CLNCT07149376 To Assess the Efficacy of a Toothpaste Containing 8% Arginine as Compared to Colgate Cavity Protection Toothpaste in the Reduction of Dentinal Hypersensitivity.Sensitivity, Toothcompleted84
2025-10-15P2Novartis Pharmaceuticals NVSNCT03874858 A Study of Full Treatment-free Remission in Patients With Chronic Myeloid LeukemiaChronic Myeloid Leukemiaterminated135
2025-10-15 est.P2Xencor, Inc. XNCRNCT05032040 A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesOvarian Cancer; Clear Cell Carcinoma; Endometrial Cancer; Cervical Carcinoma; Metastatic Castration-active not recruiting170
2025-10-15P1/P2K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT05198804 A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerOvarian Cancer; Platinum-resistant Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Canccompleted117
2025-10-15 est.P2Shanghai Henlius BiotechNCT05239650 Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRCCRCunknown50
2025-10-15P3Novo Nordisk A/S NVONCT05726227 A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose WeightObesityactive not recruiting212
2025-10-15P2GenfitNCT05900050 Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®Acute-On-Chronic Liver Failure; Ascitesterminated15
2025-10-15 est.P3Suzhou Alphamab Co., Ltd.NCT06312475 Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With InhibitorsHemophilia A With Inhibitor; Hemophilia B With Inhibitoractive not recruiting53
2025-10-15P2AstraZeneca AZNNCT06435273 Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With AsthmaAsthmacompleted36
2025-10-15 est.P2Shanghai SIMR Biotechnology Co., Ltd.NCT06577558 Efficacy and Safety of SR1375 in Adult Patients With CAPCommunity-acquired Pneumoniarecruiting240
2025-10-15P2Regeneron Pharmaceuticals REGNNCT06833190 REGN5381 in Adult Participants With Uncontrolled HypertensionUncontrolled Hypertensionterminated34
2025-10-15P3Laboratorios Silanes S.A. de C.V.NCT06916884 Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus DesloratadineAllergic Rhinitiscompleted70
2025-10-15P3R-PharmNCT07386938 A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients WLocally Advanced Breast Cancer; Metastatic Breast Canceractive not recruiting246
2025-10-16P3Neurocrine Biosciences NBIXNCT05206513 Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral PalsyDyskinesia; Cerebral Palsycompleted86
2025-10-16P1/P2Kineta Inc.NCT05708950 A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)Cancer; Solid Tumor; Melanoma; Carcinoma; Sarcoma; Lung Cancer; Prostate Cancer; Breast Cancer; Colocompleted40
2025-10-16P3Merck Sharp & Dohme LLC MRKNCT05766501 A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously ReceivHIV Infectionactive not recruiting641
2025-10-16P2argenx ARGXNCT05907096 ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft FunctionDelayed Graft Functionactive not recruiting103
2025-10-16P2CatalYm GmbHNCT06059547 Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder CancerBladder Cancer; Adult Solid Tumorcompleted31
2025-10-16P2Pacira Pharmaceuticals, Inc PCRXNCT06977568 A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the HipOsteoarthritis of Hipterminated1
2025-10-17P2Sintetica SANCT03918798 The Efficacy and Safety of Chloroprocaine 1% and 2% in Pediatric PopulationHernia, Inguinal; Flat Footcompleted164
2025-10-17P2Janssen Research & Development, LLCNCT04619420 A Study of JNJ-63733657 in Participants With Early Alzheimer's DiseaseAlzheimer Disease; Cognitive Dysfunction; Dementiaterminated523
2025-10-17P1/P2Merck Sharp & Dohme LLC MRKNCT04700072 Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain MetastaMelanomacompleted56
2025-10-17 est.P1/P2Salubris Biotherapeutics IncNCT05620134 Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic CancerCancer; Tumor, Solid; Advanced Solid Tumor; Metastatic Cancer; Melanoma; Colorectal Cancer; Non-smalunknown263
2025-10-17P2Chengdu Suncadia Medicine Co., Ltd.NCT06137768 A Trial of HRS-5965 Tablets in Primary IgA NephropathyPrimary IgA Nephropathycompleted123
2025-10-17P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06304974 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01Esophageal Squamous Cell Carcinomaactive not recruiting497
2025-10-17P3Takeda TAKNCT06323356 A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisGeneralized Pustular Psoriasis; Erythrodermic Psoriasiscompleted18
2025-10-17P3Pharvaris Netherlands B.V. PHVSNCT06343779 Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaHereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angiocompleted134
2025-10-17P2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06451640 A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal PolypsChronic Rhinosinusitis With Nasal Polypscompleted59
2025-10-17P1/P2Antiva BiosciencesNCT06491446 Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal InsertsHuman Papillomavirus Infectioncompleted141
2025-10-17P2Dizal PharmaceuticalsNCT06511895 AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)Peripheral T Cell Lymphomacompleted57
2025-10-18P2Eli Lilly and Company LLYNCT06220669 A Study of LY3541860 in Adult Participants With Relapsing Multiple SclerosisMultiple Sclerosisterminated65
2025-10-18P3Teikoku Seiyaku Co., Ltd.NCT06866613 Phase III Trial to Evaluate the Efficacy and Safety in Patients With Ankle Sprains.Ankle Sprainscompleted69
2025-10-20P3AbbVie ABBVNCT04686136 A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic MigraineEpisodic Migraine; Chronic Migrainecompleted596
2025-10-20P2/P3Ultragenyx Pharmaceutical Inc RARENCT05125809 Setrusumab vs Placebo for Osteogenesis ImperfectaOsteogenesis Imperfectaactive not recruiting183
2025-10-20P3Ono Pharmaceutical Co., Ltd.NCT05144854 A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative UnGastric Canceractive not recruiting626
2025-10-20P3ModernaTX, Inc.NCT05436834 A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of AgeSARS-CoV-2completed1807
2025-10-20P3Corxel PharmaceuticalsNCT06116968 An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCMObstructive Hypertrophic Cardiomyopathycompleted40
2025-10-20P3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT06554847 Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic DermatitisDermatitis, Atopic; Eczema, Atopiccompleted417
2025-10-20 est.P3Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.NCT06942793 A Study to Evaluate the Efficacy and Safety of Treatment With CsA-PG Ophthalmic Gel in Dry Eye PatientsDry Eye Diseasenot yet recruiting396
2025-10-21P2Sanofi SNYNCT05156710 BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)Transplant Rejectionactive not recruiting48
2025-10-21P2/P3Intercept PharmaceuticalsNCT06121375 Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric PartBiliary Atresiaterminated28
2025-10-21P3Intercept PharmaceuticalsNCT06488911 To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and BezafibratePrimary Biliary Cholangitisterminated62
2025-10-21P2GlaxoSmithKlineNCT06663436 A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in InfantsDiarrhoeacompleted200
2025-10-21P3Daewon Pharmaceutical Co., Ltd.NCT07444762 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421APrimary Hypercholesterolemia; Mixed Dyslipidemiacompleted184
2025-10-22P1/P2TransgeneNCT04725331 A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid TumorsMetastatic Cancer; Soft Tissue Sarcoma; Merkel Cell Carcinoma; Melanoma; Triple Negative Breast Cancterminated31
2025-10-22P2K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT04814108 A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous CarcinomaUterine Serous Carcinomacompleted92
2025-10-22P2Soligenix SNGXNCT05442190 Topical SGX302 for Mild-to-Moderate PsoriasisPsoriasis; Plaque Psoriasis; Psoriasis Vulgariscompleted15
2025-10-22P2Boehringer IngelheimNCT05559580 A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis SymptomsScleroderma, Systemiccompleted214
2025-10-22P3Astellas Pharma IncNCT06206408 A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through MenopauseHot Flashescompleted410
2025-10-22P2Nido Biosciences, Inc.NCT06411912 A Study of NIDO-361 in Patients With SBMASpinal and Bulbar Muscular Atrophy; Kennedy's Diseasecompleted54
2025-10-22P2Chongqing Claruvis Pharmaceutical Co., Ltd.NCT06481475 A Study to Investigate the Safety and Efficacy of YY003 in Adults With Moderate to Severe Glabellar LinesModerate to Severe Glabellar Linescompleted153
2025-10-22 est.P3Hansoh BioMedical R&D CompanyNCT06672393 A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque PsoriasisPsoriasisunknown375
2025-10-22P2The United Bio-Technology (Hengqin) Co., Ltd.NCT07177469 UBT251 Injection Phase II Study (Overweight or Obesity)Obesity &Amp; Overweightcompleted205
2025-10-22P2Traditional Naturals Research Inc.NCT07809282 A Study of Mitragynine Formulations for Exercise-Induced Muscle Soreness in Healthy AdultsDelayed Onset Muscle Soreness (DOMS); Exercise-Induced Muscle Sorenesscompleted100
2025-10-23P3BayerNCT05686070 A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic AttacPrevention of Ischemic Stroke; Acute Non-cardioembolic Ischemic Stroke; High-risk Transient Ischemiccompleted12327
2025-10-23P3Ultragenyx Pharmaceutical Inc RARENCT05768854 Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis ImperfectaOsteogenesis Imperfectaactive not recruiting69
2025-10-23P2Sanofi SNYNCT06058156 Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic DermatitisAtopic Dermatitisterminated70
2025-10-23P3Hangzhou Highlightll Pharmaceutical Co., LtdNCT06396026 A Study of Efficacy and Safety of TLL-018 in CSU ParticipantsChronic Spontaneous Urticariaactive not recruiting440
2025-10-23P2Pfizer PFENCT06717425 A Study to Learn About the Study Medicine Called PF-07976016 in Adults With ObesityObesitycompleted263
2025-10-24P1/P2Sotio Biotech Inc.NCT05120271 BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid TumorsHepatocellular Carcinoma; Squamous Cell Carcinoma of the Lung; Merkel Cell Carcinoma; Myxoid/Round Cactive not recruiting7
2025-10-24P2/P3Alume Biosciences, Inc.NCT06227585 Feasibility and Efficacy Study for Bevonescein-Assisted Nerve Visualization in Head & Neck SurgeryHead and Neck Surgerycompleted155
2025-10-24P2BayerNCT06522997 A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney DiseaseChronic Kidney Diseasecompleted1222
2025-10-24P2Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT06693843 A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight Obesity, Overweight, or Chronic Weight Managementcompleted230
2025-10-25 est.P3AkesoNCT06371157 A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Hepatocellular Carcinomarecruiting469
2025-10-26P2Xiamen Amoytop Biotech Co., Ltd.NCT06552429 Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETEssential Thrombocythemiarecruiting27
2025-10-27P3Biohaven Pharmaceuticals, Inc. BHVNNCT04641143 Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive DisorderObsessive-Compulsive Disordercompleted456
2025-10-27P3Merck Sharp & Dohme LLC MRKNCT04700124 Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) Bladder Canceractive not recruiting808
2025-10-27P2GlaxoSmithKlineNCT04880031 A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an ExtensionNonalcoholic Steatohepatitis (NASH)completed231
2025-10-27P3Alume Biosciences, Inc.NCT05377554 Bevonescein for Intra-Operative Nerve Visualization in Head and Neck SurgerySurgerycompleted154
2025-10-27P1/P2Antiva BiosciencesNCT05502367 A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial NeoplasiaCervical Intraepithelial Neoplasiaterminated44
2025-10-27P1/P2AnaCardio ABNCT05642507 Phase Ib/IIa Trial With AC01 in Patients With HFrEFHeart Failure With Reduced Ejection Fractioncompleted58
2025-10-27P2TBF Genie TissulaireNCT06034262 Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of PIP Joint OsteoarthritisOsteoarthritis Handterminated1
2025-10-27P2Diasome PharmaceuticalsNCT06238778 Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin DegludecDiabetes Mellitus, Type 1completed227
2025-10-27P3Gilead Sciences GILDNCT06333808 Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With BiktarvyHIV-1-infectionactive not recruiting577
2025-10-28P3GlaxoSmithKlineNCT04965636 Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)Hypereosinophilic Syndromecompleted16
2025-10-28P3Takeda TAKNCT05084053 A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP); Multifocal Motor Neuropathy (MMN)completed26
2025-10-28P2Intra-Cellular Therapies, Inc.NCT05766813 Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's DiseaseParkinson Diseasecompleted79
2025-10-28 est.P3Mezzion Pharma Co. LtdNCT05918211 Fontan Udenafil Exercise Longitudinal Assessment Trial - 2Single Ventricle Heart Diseaserecruiting436
2025-10-28P2AstraZeneca AZNNCT06020014 Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABAAsthmacompleted339
2025-10-28P2NMD Pharma A/SNCT06482437 Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth DiseaseCharcot-Marie-Tooth Diseasecompleted81
2025-10-28P2Chong Kun Dang PharmaceuticalNCT06954766 Initial Pilot Study to Evaluate the Safety and Temporary Symptom Improvement Efficacy of CKD-981Knee Osteoarthritiscompleted100
2025-10-30P3Amgen AMGNNCT04175613 A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque PsoriasisPsoriasiscompleted160
2025-10-30P1/P2NETRIS PharmaNCT04652076 GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or PembrolizumabEndometrial Carcinoma; Cervix Carcinomaactive not recruiting240
2025-10-30P2ITB-Med LLCNCT04803006 A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)Kidney Transplantationterminated4
2025-10-30P1/P2CanariaBio Inc.NCT04938583 Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian CancerOvarian Cancer by FIGO Stage; Ovarian Cancer Stage III; Ovarian Cancer Stage IVactive not recruiting54
2025-10-30P2/P3Agios Pharmaceuticals, Inc. AGIONCT05031780 A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)Sickle Cell Diseaseactive not recruiting286
2025-10-30 est.P1/P2Beijing Konruns Pharmaceutical Co., Ltd.NCT05260385 To Evaluate KC1036 in the Patients with Advanced Digestive System TumorsDigestive System Tumorsunknown133
2025-10-30 est.P2Shanghai Kechow Pharma, Inc.NCT05331105 HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasNeurofibromatosis 1; Plexiform Neurofibromasrecruiting70
2025-10-30P3Takeda TAKNCT05513586 A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) ParticipantsPrimary Immunodeficiency Diseases (PID)completed15
2025-10-30 est.P2FAScinate Therapeutics Inc.NCT05670782 A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's DiseaseParkinson Diseaseunknown314
2025-10-30P2Technophage, SANCT05948592 Bacteriophage Therapy TP-102 in Patients With Diabetic Foot InfectionDiabetic Foot Infectioncompleted76
2025-10-30 est.P2Keymed Biosciences Co.LtdNCT06525597 Study of Stapokibart Injection in Patients With Allergic RhinitisAllergic Rhinitisunknown120
2025-10-30 est.P2Hansoh BioMedical R&D CompanyNCT06594965 A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic SyndromesMyelodysplastic Syndromes; Anemia; MDS; Bone Marrow Diseaseunknown176
2025-10-30P2Shanghai Bovax Biotechnology Co., Ltd.NCT06756269 To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 YearsHPV Infection; HPV-Related Carcinoma; HPV-Related Intraepithelial Neoplasia; Genital Wartrecruiting330
2025-10-30 est.P2Alphyn BiologicsNCT06855745 Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.Atopic Dermatitis (Eczema); Atopic Dermatitis Eczema; Atopic Dermatitis; Atopic Dermatitis (AD); Eczrecruiting72
2025-10-30P3Laboratorios Silanes S.A. de C.V.NCT06863636 Efficacy and Safety of Celecoxib/Acetaminophen Versus Celecoxib for Diagnosed Osteoarthritis in Acute ExacerbationJoint Pain; Knee Osteoarthritis; Hip Osteoarthritiscompleted231
2025-10-30 est.P2Zhejiang Wenda Pharma Technology LTD.NCT06912165 A Study of WD-890 in Participants With Moderate-to-Severe Plaque PsoriasisBrief Description of Focus of Studyrecruiting140
2025-10-31P2Merck Sharp & Dohme LLC MRKNCT04165083 KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-prCarcinoma, Non-Small-Cell Lungcompleted100
2025-10-31 est.P1/P2Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT04632108 A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic SoliMalignant Solid Tumoractive not recruiting199
2025-10-31P3Chiesi Farmaceutici S.p.A.NCT04636801 A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in SubjeChronic Obstructive Pulmonary Diseaseterminated4710
2025-10-31P1/P2GeoVax, Inc. GOVXNCT04639466 A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 InfectionCOVID-19 Infectioncompleted119
2025-10-31P2Bristol-Myers Squibb BMYNCT05413018 An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete RemissionLeukemia, Myeloid, Acuteactive not recruiting34
2025-10-31 est.P1/P2AskGene Pharma, Inc.NCT05632939 ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.Gastric Cancer; Gastroesophageal Cancer (GC)active not recruiting62
2025-10-31 est.P2CellSight Technologies, Inc.NCT06084806 Test-retest Evaluation of [18F]F-AraG PETNon-small Cell Lung Cancerunknown10
2025-10-31P1/P2AstraZeneca AZNNCT06179511 Study of AZD9829 in CD123+ Hematological MalignanciesHematological Malignanciescompleted56
2025-10-31P2Cybrexa TherapeuticsNCT06315491 A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian CancerPlatinum-resistant Ovarian Cancer; Refractory Ovarian Carcinomaterminated40
2025-10-31P3VistaGen Therapeutics, Inc. VTGNNCT06358651 Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)Social Anxiety Disordercompleted238
2025-10-31 est.P1/P2Hanx Biopharmaceuticals (Wuhan) Co., Ltd.NCT06649708 HX044,FIH Study in Patients with Advanced Solid Tumor MalignanciesAdvanced Solid Tumor Malignanciesrecruiting100
2025-10-31P1/P2Korro Bio, Inc. KRRONCT06677307 A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110Alpha-1 Anti-trypsin Deficiency; AATDterminated42
2025-10-31 est.P1/P2PT Bio FarmaNCT06690515 Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian InfantsVaccine Adverse Reaction; Vaccine Reactionunknown465
2025-10-31 est.P1/P2Luye Pharma Group Ltd.NCT06731868 Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive DyskinesiaTardive Dyskinesia (TD)recruiting120
2025-10-31 est.P1/P2Huabo Biopharm Co., Ltd.NCT06758557 A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid TumorAdvanced NSCLC; Advanced Endometrial Cancerrecruiting282
2025-10-31P2Jiangsu vcare pharmaceutical technology co., LTDNCT06891040 Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic DermatitisAtopic Dermatitiscompleted118
2025-10-31P1/P2Haihe Biopharma Co., Ltd.NCT06909877 Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell LymphomaRelapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)recruiting100

← 2025-09 | 2025-11 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.